New diabetes drug passes safety check in chile
NCT ID NCT05533632
First seen Nov 01, 2025 · Last updated Jun 06, 2026 · Updated 37 times
Summary
This study looked at how safe and tolerable a weekly injection of semaglutide (Ozempic) is for people with type 2 diabetes in Chile. 104 adults received the medicine for about 24 weeks. The goal was to track side effects and changes in blood sugar control, not to cure diabetes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Padre Hurtado
Santiago, Región Metropolitana, 8880465, Chile
-
Hospital San Juan de Dios_Santiago, Región Metropolitana
Santiago, Región Metropolitana, 8350429, Chile
-
Servicios Médicos Godoy Limitada
Santiago, Región Metropolitana, 7500710, Chile
Conditions
Explore the condition pages connected to this study.